If you’re a Medicare beneficiary who’s been struggling with obesity or related health conditions, there’s big news you need to hear. Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching a program called the Medicare GLP-1 Bridge. This short-term demonstration will give eligible Medicare Part D enrollees access to certain popular GLP-1 weight loss drugs at a much lower cost than you’d pay out of pocket.
What is the GLP-1 Bridge?
The Medicare GLP-1 Bridge is a federally run demonstration program designed to provide Medicare Part D beneficiaries with access to GLP-1 receptor agonist medications approved for weight management. These drugs, including Wegovy and Zepbound, have become widely recognized for their effectiveness in helping people achieve meaningful, sustained weight loss. Until now, Medicare hasn’t covered these medications for obesity alone. This program changes that, at least for a defined period of time.
The demonstration runs from July 1, 2026, through December 31, 2027. It operates separately from your standard Part D drug benefit, which means your Part D plan doesn’t need to include these drugs on its formulary for you to access them. CMS has set up a centralized system managed by Humana, the same company that administers the LI NET program, to handle prior authorizations, claims, and pharmacy payments. You don’t need to switch plans or take any additional enrollment steps to be considered for this benefit.
How to Qualify
Not every Medicare beneficiary will automatically qualify for the Medicare GLP-1 Bridge. To access these medications, you’ll need to be enrolled in a standalone Medicare Part D prescription drug plan or a Medicare Advantage plan that includes drug coverage, known as an MA-PD plan. Beneficiaries in Special Needs Plans and employer or union group waiver plans are also eligible. However, if you’re enrolled in a private fee-for-service plan, a PACE organization, or a similar plan type without a standalone Part D plan, you won’t be eligible to participate.
Beyond your plan type, you’ll also need to meet specific clinical criteria, and a healthcare provider must submit a prior authorization request on your behalf. To qualify, you must be at least 18 years old and fall into one of three categories based on body mass index, or BMI. The first is a BMI of 35 or higher on its own. The second is a BMI of 30 or higher along with a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or above. The third is a BMI of 27 or higher combined with a diagnosis of pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
One detail that works in your favor is that your BMI is evaluated at the time you first started GLP-1 therapy, not necessarily when your provider submits the authorization request. So even if your BMI has dropped since you began treatment, you may still qualify based on where you started. If your provider needs to attest that your BMI met the threshold when therapy was initiated, they can do so as part of the prior authorization process.
Which Drugs Are Included?
Three GLP-1 medications are currently covered under the Medicare GLP-1 Bridge: Foundayo, Wegovy in both injection and tablet forms, and Zepbound, but only in the KwikPen formulation. The single-dose vial and single-dose pen versions of Zepbound aren’t covered under this program. Each medication must be prescribed specifically for weight reduction and weight maintenance, and they’re expected to be used alongside ongoing lifestyle changes that include structured nutrition and physical activity, consistent with FDA-approved labeling.
It’s also worth knowing that if you’ve been prescribed one of these medications for a condition already covered under your standard Part D benefit, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea, those prescriptions would continue to be handled through your regular Part D plan. The GLP-1 Bridge only applies to weight management uses that aren’t currently covered under standard Part D. CMS has stated it will monitor plans closely to make sure they don’t redirect coverage decisions to the Bridge when those decisions belong within the regular Part D system.
What You’ll Pay at the Pharmacy
One of the most significant advantages of the Medicare GLP-1 Bridge is its straightforward cost structure. When you pick up an eligible GLP-1 medication at a participating pharmacy, you’ll pay a flat $50 copay per monthly supply. Manufacturers provide these drugs to the program at a net price of $245 per monthly supply, and the central processor handles the remaining reimbursement to the pharmacy, including a dispensing fee and applicable sales tax.
There are a few financial details that are important to understand. The $50 copay you pay won’t count toward your true out-of-pocket costs under your Part D plan, and the cost of the drug won’t count toward your gross covered prescription drug costs either. This benefit exists completely outside of your normal Part D cost-tracking, which means it won’t affect where you stand in the coverage phases of your plan.
Low-income subsidies don’t apply to the GLP-1 Bridge copay, so everyone who’s enrolled pays the same $50 flat rate regardless of their income level. Manufacturer coupons and discount cards can’t be used through this program either, so don’t count on those to further reduce your expense at the pharmacy counter.
How to Access the Program
Getting access to the Medicare GLP-1 Bridge starts with a conversation with your healthcare provider. Your doctor or prescribing provider will need to submit a prior authorization request directly to the central processor. They don’t need to be enrolled in Medicare themselves to do this, but they must not appear on Medicare’s Preclusion List. Once prior authorization is approved, your provider will write a prescription for an eligible GLP-1 drug, and you’ll be able to fill it at a participating pharmacy.
Pharmacies don’t need to separately sign up for the GLP-1 Bridge. CMS has established a specific Bank Identification Number and Processor Control Number for the program, 028918 MEDDGLP1BR, which your pharmacist will use when processing your claim. It routes the claim to the central processor rather than through your regular Part D plan. Claims are processed electronically, and paper claims won’t be accepted. If your Part D plan receives a prior authorization request for a GLP-1 drug that falls under the Bridge, CMS encourages the plan to redirect that provider to the central processor.
Conclusion
The Medicare GLP-1 Bridge is great news for seniors who’ve been working hard to manage their weight and protect their long-term health. If you’re living with obesity alongside conditions like high blood pressure, kidney disease, or a history of heart attack or stroke, this program could give you access to effective weight loss medication at a cost that’s genuinely manageable. Talk to your doctor prior to July 1, 2026 to find out whether you qualify. For more information about Medicare GLP-1 coverage, please call 866-633-4427 to speak with a Senior Healthcare Solutions Medicare expert.
